Background Considerable evidence on the costs and cost-effectiveness of biomedical, non-
surgical interventions to prevent human immunodeficiency virus (HIV) transmission has …

Risk of HIV infection is high in Chinese MSM, with an annual HIV incidence ranging from
3.41 to 13.7/100 person-years. Tenofovir-based PrEP is effective in preventing HIV …

Abstract Background and Objective Although HIV prevention science has advanced over the
last four decades, evidence suggests that prevention technologies do not always reach their …

Abstract Introduction In 2014, the Government of Thailand recommended pre‐exposure
prophylaxis (PrEP) as an additional HIV prevention programme within Thailand's National …

Pre-exposure prophylaxis (PrEP) targeting high-risk men who have sex with men (MSM) has
been shown to be a cost-effective HIV control measure. However, the approach could be a …

The purpose of this scoping review is to establish the state of the art on economic
evaluations in the field of HIV/STI prevention in high-income countries with concentrated …

Objective To evaluate the cost-effectiveness of financial incentives for human
immunodeficiency virus (HIV) viral suppression compared to standard of care. Study Design …

Promising multi-dose HIV vaccine regimens are being tested in trials in South Africa. We
estimated the potential epidemiological and economic impact of HIV vaccine campaigns …

Introduction: Promising HIV vaccine candidates are steadily progressing through the clinical
trial pipeline. Once available, HIV vaccines will be an important complement but also …

This chapter reviews scientific studies of the risk of HIV and other sexually transmitted
infections among male sex workers. It reports on sexual risk behavior as well as …